The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals…
Uterine fibroids are characterized by heavy menstrual bleeding (menorrhagia), pelvic pressure due to increased uterine bulk, abdominal and back pain, and fertility issues. Disease management may…
Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
The treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals…
Hemophilia A patients are a heterogeneous cohort. The tendency to bleed is highly individual, resulting in a complex management landscape. Two core therapeutic approaches are employed: (1)…
Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain therapy market. Prescription treatment…
Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug…
The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…
A variety of analgesic products are available to specialists managing postoperative pain in the United States, although the majority of these medicines are available as inexpensive generics…
MARKET OUTLOOK Tumor necrosis factor-alpha (TNF-α) inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) are approved for the treatment of…
MARKET OUTLOOK Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key…
Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain therapy market and thus is an attractive…